Yuflyma (Adalimumab-Aaty) for Hidradenitis Suppurativa

Yuflyma (adalimumab-aaty) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe hidradenitis suppurativa.

How Yuflyma Works and How It’s Taken

Yuflyma works by blocking tumor necrosis factor (TNF)-alpha, a protein in the body that causes inflammation. In moderate to severe hidradenitis suppurativa, this blocks TNF-alpha and changes some inflammatory responses in the body. The exact way it works in hidradenitis suppurativa is not fully known.

Doctors prescribe Yuflyma for adults with moderate to severe hidradenitis suppurativa. By targeting inflammation, the medication may help manage symptoms and slow disease activity.

Yuflyma is given as an injection under the skin. Treatment starts with a higher starter dose, followed by another dose two weeks later. After that, it is taken every week or every other week.

After proper training, people or their caregivers can give the injections at home.

Yuflyma Side Effects

In clinical studies of Yuflyma for moderate to severe hidradenitis suppurativa in adults, the most common side effects that occurred were:

Infections (such as upper respiratory infections and sinus infections)
Injection site reactions (such as discoloration, itching, bleeding, pain, or swelling where the shot is given)
Headache
Rash

Serious Side Effects and Warnings

Yuflyma can cause serious side effects that require immediate medical attention. These include:

Serious infections — Your immune system may not fight infections as well, including tuberculosis, invasive fungal infections, and other infections that can spread through the body.
Cancer — This includes lymphoma and other cancers.
Severe allergic reactions — These include anaphylaxis and angioedema, which can cause swelling or trouble breathing.
Hepatitis B virus reactivation — The virus can become active again in people who carry it.
Nervous system problems — Rare demyelinating disorders, which affect the protective covering of nerves, such as optic neuritis or Guillain-Barré syndrome, can develop.
Serious blood problems — Rare conditions like pancytopenia or aplastic anemia, which can cause symptoms such as unusual bruising, bleeding, or persistent fever, may develop.
Heart failure — This includes new or worsening congestive heart failure.
Lupus-like syndrome — An autoimmune reaction that can cause symptoms similar to lupus may develop.

Get medical help right away if you think you are having a serious reaction.

How To Save on Yuflyma

Celltrion USA, the manufacturer of Yuflyma, offers the Celltrion Cares Co-Pay Assistance Program. Eligible people with commercial insurance may pay as little as $0 per month.

The Celltrion Cares Co-Pay Assistance Program provides copay savings for Yuflyma, while the Celltrion Connect Patient Support Program offers personalized help with insurance, prior authorization and appeals, and access to financial support and day-to-day resources. To learn more, visit the Celltrion Cares Co-Pay Assistance Program website or the Celltrion Connect Patient Support Program website, or call 877-812-6662.

What To Know Before Taking Yuflyma

Before starting Yuflyma, your doctor will check you for active tuberculosis (TB), hidden (latent) TB, and may also test for hepatitis B (a virus that affects the liver). Do not start Yuflyma if you have an active infection.

People taking Yuflyma can receive most vaccines, but they should not get live vaccines while on treatment.

Tell your doctor if you have any allergies to adalimumab-aaty or any ingredients in Yuflyma.

Tell your doctor about all medicines you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.

Tell your doctor if you have any infections, have had infections that keep coming back, have traveled to areas where certain infections are common, or have had cancer or nervous system problems.

Yuflyma is also FDA approved to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and uveitis.

If you miss a dose, take it as soon as possible. Then continue your regular schedule.

If you are pregnant, planning to become pregnant, or breastfeeding while taking Yuflyma, talk with your doctor about the risks and benefits.

Community FAQs

These answers are fact-checked by our editorial staff.

How effective is Yuflyma in hidradenitis suppurativa?
In clinical studies, adalimumab, the reference product for Yuflyma, was studied in people with hidradenitis suppurativa. The safety profile in people with hidradenitis suppurativa was consistent with the known safety profile of adalimumab.

In two studies, about 22 out of 100 people who stopped treatment after the main study period experienced a flare (worsening) of their condition. These results suggest that staying on treatment may help keep symptoms under control for some people.

How often is Yuflyma taken for hidradenitis suppurativa?
Yuflyma is first given as higher starting doses. This includes 160 milligrams on day 1. This dose may be given in one day or split over two days. Then 80 milligrams are given on day 15.

Starting on day 29, Yuflyma is taken regularly as either 40 milligrams every week or 80 milligrams every other week. Your doctor will choose the schedule that is right for you.

What tests or monitoring are needed with Yuflyma for hidradenitis suppurativa?
Before starting Yuflyma, your doctor will test you for TB, including latent (hidden) TB, and may check your risk for hepatitis B. While you are taking Yuflyma, your doctor will watch for signs of infection, including TB.

Your doctor will also check for serious side effects, such as problems with your blood, liver, or nervous system, which controls your brain and nerves. It is important to have regular checkups so your doctor can make sure the medicine is working safely.